medicalmarketnews.com
Idorsia Joins Hands with U.S. Neurocrine in $400 Million Epilepsy Drug Pact - Medical Market News
Swiss biotech organization Idorsia on Friday lifted the cap off 2019 agreement for its investigational epilepsy medicine, revealing the pact that’s potentially worth over $400 million is with U.S.-based mostly Neurocrine Biosciences. In 2019, Idorsia won a $5 million payment for a licensing option for ACT-709478; however, stored Neurocrine’s identity a secret. Their settlement calls …